ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease
Open accessPublished version of a preprint
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Protein-truncating variants (PTVs) affecting dyslipidemia risk may point to therapeutic targets for cardiometabolic disease. Our objective was to identify PTVs that were associated with both lipid levels and the risk of coronary artery disease (CAD) or type 2 diabetes (T2D) and assess their possible associations with risks of other diseases. To achieve this aim, we leveraged the enrichment of PTVs in the Finnish population and tested the association of low-frequency PTVs in 1,209 genes with serum lipid levels in the Finrisk Study (n = 23,435). We then tested which of the lipid-associated PTVs were also associated with the risks of T2D or CAD, as well as 2,683 disease endpoints curated in the FinnGen Study (n = 218,792). Two PTVs were associated with both lipid levels and the risk of CAD or T2D: triglyceride-lowering variants in ANGPTL8 (-24.0[-30.4 to -16.9] mg/dL per rs760351239-T allele, P = 3.4 × 10 −9 ) and ANGPTL4 (-14.4[-18.6 to -9.8] mg/dL per rs746226153-G allele, P = 4.3 × 10 −9 ). The risk of T2D was lower in carriers of the ANGPTL4 PTV (OR = 0.70[0.60–0.81], P = 2.2 × 10 −6 ) than noncarriers. The odds of CAD were 47% lower in carriers of a PTV in ANGPTL8 (OR = 0.53[0.37–0.76], P = 4.5 × 10 −4 ) than noncarriers. Finally, the phenome-wide scan of the ANGPTL8 PTV showed that the ANGPTL8 PTV carriers were less likely to use statin therapy (68,782 cases, OR = 0.52[0.40–0.68], P = 1.7 × 10 −6 ) compared to noncarriers. Our findings provide genetic evidence of potential long-term efficacy and safety of therapeutic targeting of dyslipidemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationXu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Howie, B. N., Donnelly, P., & Marchini, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000529 · Cited by 3,928 · cited 4×
“The PTVs in our secondary and tertiary analyses had IMPUTE2[34] genotype information scores above 0.”
BackgroundMethodInfluentialRobust relationship inference in genome-wide association studies
Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq559 · Cited by 3,541 · cited 1×
“edu/~wc9c/KING/) [35] kinship value to 0.”
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,358
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Zhou, W., Nielsen, J. B., Fritsche, L. G., Dey, R., Gabrielsen, M. E., Wolford, B. N., LeFaive, J., VandeHaar, P., Gagliano, S. A., Gifford, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0184-y · Cited by 1,544
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Denny, J. C., Bastarache, L., Ritchie, M. D., Carroll, R. J., Zink, R., Mosley, J. D., Field, J. R., Pulley, J. M., Ramirez, A. H., Bowton, E., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2749 · Cited by 1,013
Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885 · cited 1×
“LPL inhibition is important because it is the mechanism by which several triglyceride-lowering drugs currently under development work [8,9,12].”
BackgroundCommon variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862 · cited 1×
“This is in line with genetic evidence of triglycerides being a causal factor for CAD risk [29].”
Self-citationFINEMAP: efficient variable selection using summary data from genome-wide association studies
Benner, C., Spencer, C. C. A., Havulinna, A. S., Salomaa, V., Ripatti, S., & Pirinen, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw018 · Cited by 815
Self-citationGenetics of blood lipids among ∼300,000 multi-ethnic participants of the Million Veteran Program
Global Lipids Genetics Consortium, Klarin, D., Myocardial Infarction Genetics (MIGen) Consortium, The Geisinger-Regeneron DiscovEHR Collaboration, Program, T. V. M. V., Damrauer, S. M., Cho, K., Sun, Y. V., Teslovich, T. M., Honerlaw, J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0222-9 · Cited by 625
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18925 · Cited by 560
Exome-wide association study of plasma lipids in >300,000 individuals
Charge Diabetes Working Group, Liu, D. J., The EPIC-InterAct Consortium, EPIC-CVD Consortium, GOLD Consortium, Program, V. M. V., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3977 · Cited by 540
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Thirty-five-year trends in cardiovascular risk factors in Finland
Vartiainen, E., Laatikainen, T., Peltonen, M., Juolevi, A., Mannisto, S., Sundvall, J., Jousilahti, P., Salomaa, V., Valsta, L., & Puska, P. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyp330 · Cited by 499
Self-citationInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497 · cited 3×
“Nominal associations (P 0.05) between lower triglyceride levels and protein-truncating variation in ANGPTL8[19] and ANGPTL4[9], as well as between CETP protein-truncating variation and higher HDL cholesterol levels [20], have also been reported.”
BackgroundInfluentialCoding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F. J., Desvergne, B., & Wahli, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004029200 · Cited by 489
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
The impact of low-frequency and rare variants on lipid levels
ENGAGE Consortium, Surakka, I., Horikoshi, M., Mägi, R., Sarin, A.-P., Mahajan, A., Lagou, V., Marullo, L., Ferreira, T., Miraglio, B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3300 · Cited by 351 · cited 1×
“Recent surveys on the protein-coding variation in lipid-associated loci [4,5,7] have implicated likely causal genes via low-frequency coding variants.”
BackgroundSelf-citationPeloso, G. M., Auer, P. L., Bis, J. C., Voorman, A., Morrison, A. C., Stitziel, N. O., Brody, J. A., Khetarpal, S. A., Crosby, J. R., Fornage, M., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.01.009 · Cited by 317
Wang, Y., Quagliarini, F., Gusarova, V., Gromada, J., Valenzuela, D. M., Cohen, J. C., & Hobbs, H. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315292110 · Cited by 317
Kempe, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki836 · Cited by 284
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels
Emdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Won, H.-H., Peloso, G. M., Stitziel, N. O., Nomura, A., Zekavat, S. M., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.033 · Cited by 244 · cited 1×
“A study assessing this question exists for the chief lipoprotein(a)-modulating gene LPA [16].”
BackgroundA Test in Context: Lipid Profile, Fasting Versus Nonfasting
Nordestgaard, B. G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.006 · Cited by 223
ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance
Haller, J. F., Mintah, I. J., Shihanian, L. M., Stevis, P., Buckler, D., Alexa-Braun, C. A., Kleiner, S., Banfi, S., Cohen, J. C., Hobbs, H. H., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075689 · Cited by 199
ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
Chi, X., Britt, E. C., Shows, H. W., Hjelmaas, A. J., Shetty, S. K., Cushing, E. M., Li, W., Dou, A., Zhang, R., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.014 · Cited by 174
Badellino, K. O., Wolfe, M. L., Reilly, M. P., & Rader, D. J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030022 · Cited by 173
Diabetes and cardiovascular disease: The Framingham study
Kannel, W. B. (1975) · The American Journal of Cardiology · doi:10.1016/0002-9149(75)90692-x · Cited by 168
GLGC Consortium, Lu, X., Peloso, G. M., Liu, D. J., Wu, Y., Zhang, H., Zhou, W., Li, J., Tang, C. S.-M., Dorajoo, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3978 · Cited by 159
Gusarova, V., O’Dushlaine, C., Teslovich, T. M., Benotti, P. N., Mirshahi, T., Gottesman, O., Van Hout, C. V., Murray, M. F., Mahajan, A., Nielsen, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04611-z · Cited by 145
Ren, J., Grundy, S. M., Liu, J., Wang, W., Wang, M., Sun, J., Liu, J., Li, Y., Wu, Z., & Zhao, D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.020 · Cited by 111
Zhang, Y., Guo, X., Yan, W., Chen, Y., Ke, M., Cheng, C., Zhu, X., Xue, W., Zhou, Q., Zheng, L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02355-w · Cited by 108
Rafiee, P., Nelson, V. M., Manley, S., Wellner, M. R., Floer, M., Binion, D. G., & Shaker, R. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90428.2008 · Cited by 87
Nomura, A., Won, H.-H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86
Fu, Z., Abou-Samra, A. B., & Zhang, R. (2015) · Scientific Reports · doi:10.1038/srep18502 · Cited by 82
for the Sequencing Initiative Suomi (SISu) Project, Chheda, H., Palta, P., Pirinen, M., McCarthy, S., Walter, K., Koskinen, S., Salomaa, V., Daly, M., Durbin, R., et al. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.205 · Cited by 64
Self-citationDang, F., Wu, R., Wang, P., Wu, Y., Azam, M. S., Xu, Q., Chen, Y., & Liu, Y. (2016) · Scientific Reports · doi:10.1038/srep36926 · Cited by 57
Gastroesophageal reflux activates the NF-κB pathway and impairs esophageal barrier function in mice
Fang, Y., Chen, H. H., Hu, Y., Djukic, Z., Tevebaugh, W., Shaheen, N. J., Orlando, R. C., Hu, J., & Chen, X. L. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00438.2012 · Cited by 54
Endothelial Lipase Modulates Monocyte Adhesion to the Vessel Wall
Kojma, Y., Hirata, K., Ishida, T., Shimokawa, Y., Inoue, N., Kawashima, S., Quertermous, T., & Yokoyama, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411112200 · Cited by 52
Goldman, A. J., Chen, H. D. R., Roesly, H. B., Hill, K. A., Tome, M. E., Dvořák, B., Bernstein, H., & Dvorak, K. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00461.2010 · Cited by 51
Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population
Lim, E. T., Würtz, P., Havulinna, A. S., Palta, P., Tukiainen, T., Rehnström, K., Esko, T., Mägi, R., Inouye, M., Lappalainen, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004494 · Cited by 49
Self-citationHara, T., Ishida, T., Kojima, Y., Tanaka, H., Yasuda, T., Shinohara, M., Toh, R., & Hirata, K.-I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m008417 · Cited by 38
Type 2 diabetes mellitus and endothelial lipase
Shiu, S. W. M., Tan, K. C. B., Huang, Y., & Wong, Y. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.03.012 · Cited by 28
Clapham, K. R., Chu, A. Y., Wessel, J., Natarajan, P., Flannick, J. A., Rivas, M. A., Sartori, S., Mehran, R., Baber, U., Fuster, V., et al. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0088-8 · Cited by 11
Cited by
FinnGen provides genetic insights from a well-phenotyped isolated population
Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K. M., Reeve, M. P., Laivuori, H., Aavikko, M., Kaunisto, M. A., et al. (2023) · Nature · doi:10.1038/s41586-022-05473-8 · Cited by 4,233
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“35 Currently, given that no clear signal indicates which features of TRL give rise to risk, and recognizing the need for further study to identify the best index of ASCVD risk, plasma TG levels are a reasonable surrogate.”
BackgroundKurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K., Reeve, M. P., Laivuori, H., Aavikko, M., Kaunisto, M. A., et al. (2022) · medRxiv · doi:10.1101/2022.03.03.22271360 · Cited by 397
Self-citationGenome-wide association analysis of plasma lipidome identifies 495 genetic associations
Ottensmann, L., Tabassum, R., Ruotsalainen, S. E., Gerl, M. J., Klose, C., Widén, E., FinnGen, Simons, K., Ripatti, S., & Pirinen, M. (2023) · Nature Communications · doi:10.1038/s41467-023-42532-8 · Cited by 269
Self-citationLipoprotein lipase and its regulators: an unfolding story
Wu, S. A., Kersten, S., & Qi, L. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.11.005 · Cited by 225
Metadata
- Authors
- Helkkula, P., Kiiskinen, T., Havulinna, A. S., Karjalainen, J., Koskinen, S., Salomaa, V., Daly, M. J., Palotie, A., Surakka, I., Ripatti, S., & FinnGen
- Affiliations
- University of Helsinki (FI)
- Broad Institute (US)
- Finnish Institute for Health and Welfare (FI)
- Corresponding author
- Ripatti, Samuli
- ORCID
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-04-28
- Volume
- 17
- Issue
- 4
- Pages
- e1009501
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC8109807
- OpenAlex
- W3157950658
- Cited by
- 47
- References
- 58
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 8 · 2021: 8
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-05-10)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Työväentutkimus Vuosikirja (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- WOS
- Funders
- Business Finland (HUS 4685/31/2016 and UH 4386/31/2016)
- Sigrid Juséliuksen Säätiö
- University of Helsinki HiLIFE
- Academy of Finland Center of Excellence in Complex Disease Genetics (312062, 336820, 312074, 336824, 312075, 336821)
- Academy of Finland (285380, 128650, 321356)
- Horizon 2020 (101016775, 66730)
- Sydäntutkimussäätiö
- Precision Health Scholars Award from the University of Michigan Medical School
- Doctoral Programme in Population Health, University of Helsinki
- Emil Aaltosen Säätiö
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- ANGPTL8, ANGPTL4, truncating mutations, serum triglycerides, coronary artery disease, type 2 diabetes, dyslipidemia, low-frequency variants, statin therapy, phenome-wide association study, therapeutic target, cardiometabolic disease, Finnish population, FINRISK Study
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 8, Aged, Coronary Artery Disease, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Risk Factors, Triglycerides, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Peptide Hormones, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.